Abstract
OBJECTIVE: To assess the contribution of a thermogenic effect to weight loss induced by eight weeks treatment with sibutramine (15mg/d) vs placebo in obese subjects.
DESIGN: Randomised, placebo controlled, double blind study.
SUBJECTS: Thirty-two (7 male, 25 female) healthy obese body mass index (BMI) 33.9±0.5 kg/m2 subjects completed the trial.
MEASUREMENTS: Energy expenditure (EE) was measured by indirect calorimetry during a 32 h stay in a respiration chamber before and after 8 weeks treatment. Visual analogue scales were completed for assessment of appetite sensation. No dietary restriction was given.
RESULTS: Sibutramine caused a significant weight loss compared with placebo (−2.4 kg vs+0.3 kg, P<0.001). Despite the larger weight loss after 8 weeks, 24-h EE did not decrease more in the sibutramine than in the placebo group (−2.6% vs −2.5%, P=ns). When the changes in 24-h EE were adjusted for changes in body weight, 24-h EE decreased significantly less in the sibutramine group than in the placebo group (0.8% vs 3.8%, P<0.02). Sibutramine significantly decreased both hunger and anticipated food consumption, and increased satiety scores.
CONCLUSIONS: The weight reducing effect of sibutramine in humans is caused by a dual mechanism: reduction of energy intake by increasing satiety and decreasing hunger and prevention of the decline in EE that follows weight loss.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hansen, D., Toubro, S., Stock, M. et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes 23, 1016–1024 (1999). https://doi.org/10.1038/sj.ijo.0801059
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801059
Keywords
This article is cited by
-
Modeling energy intake by adding homeostatic feedback and drug intervention
Journal of Pharmacokinetics and Pharmacodynamics (2015)
-
The Effect of Tesofensine on Appetite Sensations
Obesity (2012)
-
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
International Journal of Obesity (2010)
-
Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation
Psychopharmacology (2009)
-
Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
Obesity (2008)